Testosterone therapy with Testopel® and the Esoterix Laboratory assay: A CASE study

David Seitman; Joseph Fallon; Barry Kimmels

doi:10.1016/j.eucr.2021.101714

Testosterone therapy with Testopel® and the Esoterix Laboratory assay: A CASE study

David Seitman, Joseph Fallon, Barry Kimmels

General Internal Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

We present a patient receiving Testopel® implants whose serum testosterone levels, as measured by a CDC certified assay, were accurately predicted by a multi-compartmental model. This is the first time a model has predicted measured serum testosterone levels within 4% of values calculated. To our knowledge, it was also the first time a pharmacokinetic model allowed patient targeted serum levels (peak/trough/average) to be reached within three months.

Original language	English (US)
Article number	101714
Journal	Urology Case Reports
Volume	38
DOIs	https://doi.org/10.1016/j.eucr.2021.101714
State	Published - Sep 2021

All Science Journal Classification (ASJC) codes

Urology

Access to Document

10.1016/j.eucr.2021.101714

Cite this

@article{fa3a482fac234fb4882ec697fe4a120b,

title = "Testosterone therapy with Testopel{\textregistered} and the Esoterix Laboratory assay: A CASE study",

abstract = "We present a patient receiving Testopel{\textregistered} implants whose serum testosterone levels, as measured by a CDC certified assay, were accurately predicted by a multi-compartmental model. This is the first time a model has predicted measured serum testosterone levels within 4% of values calculated. To our knowledge, it was also the first time a pharmacokinetic model allowed patient targeted serum levels (peak/trough/average) to be reached within three months.",

author = "David Seitman and Joseph Fallon and Barry Kimmels",

note = "Publisher Copyright: {\textcopyright} 2021",

year = "2021",

month = sep,

doi = "10.1016/j.eucr.2021.101714",

language = "English (US)",

volume = "38",

journal = "Urology Case Reports",

issn = "2214-4420",

publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Testosterone therapy with Testopel® and the Esoterix Laboratory assay

T2 - A CASE study

AU - Seitman, David

AU - Fallon, Joseph

AU - Kimmels, Barry

PY - 2021/9

Y1 - 2021/9

N2 - We present a patient receiving Testopel® implants whose serum testosterone levels, as measured by a CDC certified assay, were accurately predicted by a multi-compartmental model. This is the first time a model has predicted measured serum testosterone levels within 4% of values calculated. To our knowledge, it was also the first time a pharmacokinetic model allowed patient targeted serum levels (peak/trough/average) to be reached within three months.

AB - We present a patient receiving Testopel® implants whose serum testosterone levels, as measured by a CDC certified assay, were accurately predicted by a multi-compartmental model. This is the first time a model has predicted measured serum testosterone levels within 4% of values calculated. To our knowledge, it was also the first time a pharmacokinetic model allowed patient targeted serum levels (peak/trough/average) to be reached within three months.

UR - http://www.scopus.com/inward/record.url?scp=85106920094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85106920094&partnerID=8YFLogxK

U2 - 10.1016/j.eucr.2021.101714

DO - 10.1016/j.eucr.2021.101714

M3 - Article

AN - SCOPUS:85106920094

SN - 2214-4420

VL - 38

JO - Urology Case Reports

JF - Urology Case Reports

M1 - 101714

ER -

Testosterone therapy with Testopel® and the Esoterix Laboratory assay: A CASE study

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this